NVCR Q3 Results

Hey Fools,

I’ve been tracking a potential breaker call Novocure for some time now – here’s some quick links for those who are interested in following along:

https://www.fool.com/investing/2017/07/13/the-fastest-growin…

https://www.fool.com/investing/2017/08/28/if-you-love-intuit…

And the pitch that I did for Novocure on Industry Focus:

https://www.fool.com/podcasts/industry-focus/2017-10-18-heal…

Moving along to Q3 results:

P/R: https://www.novocure.com/novocure-reports-third-quarter-2017…

Transcript: https://seekingalpha.com/article/4116842-novocures-nvcr-ceo-…

+Revenue +131% to $50.1 million (ninth quarter in a row of triple-digit growth)
+1,683 active patients, up 71% (U.S. 1,234, Germany/EMEA 448, Japan 1)
+210 million lives now covered
+reimbursement clearance in Austria (first national reimbursement)
+Prescriptions received 1,076 (+56%)
+R&D costs decline by 900k to $9.3 MM thanks to trial consulsions
+Sales expense 3% (the business is scaling nicely)
+G&A expenses +20%
+$2.5 MM in cash flow from operations (first time ever!)
+Net loss $11.5 MM
+Cash balance $186.6 MM

Recruiting for two phase 3 pivotal trials – lung cancer and brain metastases from lung cancer.

Two additional phase 3 pivotal trials in pancreatic cancer and ovarian cancer planned.

Looks good to this Fool.

Brian

17 Likes